“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB‐FUBINACA in New York

  title={“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB‐FUBINACA in New York},
  author={Axel Adams and Samuel D. Banister and Lisandro Irizarry and Jordan Trecki and Michael D Schwartz and Roy R. Gerona},
  journal={The New England Journal of Medicine},
BACKGROUND New psychoactive substances constitute a growing and dynamic class of abused drugs in the United States. On July 12, 2016, a synthetic cannabinoid caused mass intoxication of 33 persons in one New York City neighborhood, in an event described in the popular press as a “zombie” outbreak because of the appearance of the intoxicated persons. METHODS We obtained and tested serum, whole blood, and urine samples from 8 patients among the 18 who were transported to local hospitals; we also… 

Figures and Tables from this paper

Review on AMB-FUBINACA one of synthetic cannabinoids present in Egypt

The toxic effect of AMB-FUBINACA as a new synthetic cannabinoid has been the focus of interest by health care professionals, as their use put the health of many humans at risk especially young adults.

Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA

The presented case shows that synthetic cannabinoids can be undetected in the blood of even seriously or fatally intoxicated people and suggests that AMB-FUBINACA and EMB-FubINACA use is dangerous to health and may lead to fatal intoxication.

4F‐MDMB‐BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework

4F‐MDMB‐BINACA is appearing with increasing frequency as a contributory factor in deaths, creating morbidity and mortality risks for drug users, and Laboratories must be aware of its presence and impact, incorporating 4F‐ MDMB‐ BINACA into workflows for detection and confirmation.

Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA.

A basic molecular pharmacology characterization of AMB-FUBINACA in comparison to traditional research cannabinoids CP55,940, WIN55,212-2, and Δ9-THC in fundamental pathways of receptor activity revealed that it is highly efficacious and potent in all pathways assayed.

Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications

This review highlights the urgent requirement for additional studies on the toxicokinetic properties of AMB-FUBINACA and ADB- fubINACA, as this is imperative to improve the methods for detecting and quantifying these drugs and to determine the best exposure markers in the various biological matrices.

Screening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC–QTOF–MS

The UHPLC–QTOF–MS method was proven to be sensitive, selective and robust for routine use for the investigated metabolites, and fulfilled the set criteria and requirements for matrix effect, extraction recovery, linearity, precision, accuracy, specificity, and stability.

Evaluation of Synthetic Cannabinoid Metabolites in Human Blood in the Absence of Parent Compounds-A Stability Assessment.

Forensic toxicologists should be aware of the results of this study as they directly impact analytical consideration for test development and implementation, as well as interpretation of findings.



An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA

A coordinated response and collaboration between law enforcement, the local public health, emergency medical services and Health Center staff, were all key interventions in preventing a more substantial public health outbreak resulting from use of a novel synthetic cannabinoid compound.

Acute kidney injury associated with smoking synthetic cannabinoid

The epidemiology of a toxicologic syndrome of acute kidney injury associated with synthetic cannabinoids is described, the toxicologic and public health investigation of the cluster is reviewed, and clinical implications of the Cluster investigation are described.

Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.

In vitro functional activities of SC designer drugs JWH-018, UR-144, PB-22, and APICA, and their respective terminally fluorinated analogues and in vivo in vivo cannabinoid type 1 receptor binding affinity evaluated in rats showed no consistent trend for increased potency of fluorinated SCs over the corresponding des-fluoro SCs in vivo.

Patterns of synthetic cannabinoid use in Australia.

The sample reported first using synthetic cannabinoids due to curiosity, legality, availability, effects, non-detection in drug testing and to reduce their cannabis use to aid the reduction or cessation of cannabis use.

Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.

In vitro and in vivo data indicate that these SCs act as highly efficacious CB receptor agonists with greater potency than Δ(9)-THC and earlier generations of SCs.